<DOC>
	<DOCNO>NCT00534274</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , positron emission tomography ( PET ) use 3'-deoxy-3'- ( 18F ) fluorothymidine , may effective assess response chemotherapy surgery treat locally advance breast cancer . PURPOSE : This clinical trial study well positron emission tomography use 3'-deoxy-3'- ( 18F ) fluorothymidine work treat woman locally advance cancer one breast receiving chemotherapy .</brief_summary>
	<brief_title>Positron Emission Tomography Using 3'-Deoxy-3'- ( 18F ) Fluorothymidine Treating Women With Locally Advanced Cancer One Breast Who Are Receiving Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy positron emission tomography ( PET ) utilize 3'-deoxy-3'- ( 18F ) fluorothymidine ( ^18F-FLT ) correctly identify response neoadjuvant chemotherapy woman locally advanced unilateral breast cancer . - Correlate PET-^18F-FLT result histological response . Secondary - Evaluate correlation early change tumor uptake ^18F-FLT first course chemotherapy complete response treatment completion . - Evaluate correlation early change tumor uptake ^18F-FLT histologic response biopsy obtain 1 course chemotherapy . - Determine initial intensity tumor uptake predictive value response chemotherapy . - Determine initial intensity tumor uptake ^18F-FLT varies accord histologic type tumor , index proliferation , tumor cellularity therapy . - Determine tumor uptake ^18F-FLT therapy varies accord histologic type tumor , index proliferation , tumor cellularity therapy . - Evaluate role TK1 kinetics ^18 F-FLT . - Analyze serum . - Research biomarkers genomics , transcription , proteomics . - Evaluate toxicity ^18F-FLT . OUTLINE : This multicenter study . Patients receive 3'-deoxy-3'- ( 18F ) fluorothymidine ( ^18F-FLT ) IV undergo positron emission tomography ( PET ) first second course neoadjuvant chemotherapy . Patients receive bisequential chemotherapy undergo ^18F-FLT-PET change drug ( usually fourth fifth course ) . All patient undergo final ^18F-FLT-PET last chemotherapy course surgery . After completion study therapy , patient follow 1 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm unilateral breast cancer T2 T3 , N , M0 Unifocal mammography ultrasound Negative cerbB2 immunohistochemistry ( IHC ) Planning neoadjuvant chemotherapy comprise anthracyclines and/or taxanes , alone combine Measurable disease ultrasound Hormone receptor status specify Exclusion criterion : Bilateral disease Multifocal tumor Invasive grade I lobular cancer Metastatic disease Stage â‰¥ T4 disease Cutaneous invasion , major adherence , inflammatory disease Tumor overexpressing cerbB2 IHC ( HER 2+++ ) Suspected clinical radiological lesion ( examine ) PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 01 Female Menopausal status specify Hematologic , hepatic , renal function normal Not pregnant nursing Fertile patient must use effective contraception Exclusion criterion : Alcohol dependency prior reaction ethanol injection Impossible receive study therapy due geographical , social , psychological reason Prisoners patient supervision PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Exclusion criterion : Participation another concurrent therapeutic study experimental drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>